Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic

Jemal, 2010, Cancer statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073

Jemal, 2010, Global patterns of rd and mortality rates and trends, Cancer Epidemiol Biomarkers Prev, 19, 1893, 10.1158/1055-9965.EPI-10-0437

Nasr, 2008, Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation, Nat Med, 14, 1333, 10.1038/nm.1891

Barbany, 2002, Complete molecular remission in chronic myelogenous leukemia after imatinib therapy, N Engl J Med, 347, 539, 10.1056/NEJM200208153470719

Hortobagyi, 2005, Trastuzumab in the treatment of breast cancer, N Engl J Med, 353, 1734, 10.1056/NEJMe058196

Geyer, 2006, Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N Engl J Med, 355, 2733, 10.1056/NEJMoa064320

Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938

Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056/NEJMoa1002011

Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945

Jimeno, 2009, KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection, J Clin Oncol, 27, 1130, 10.1200/JCO.2008.19.8168

Amado, 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol, 26, 1626, 10.1200/JCO.2007.14.7116

Lievre, 2008, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol, 26, 374, 10.1200/JCO.2007.12.5906

Sargent, 2010, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J Clin Oncol, 28, 3219, 10.1200/JCO.2009.27.1825

Olaussen, 2006, DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy, N Engl J Med, 355, 983, 10.1056/NEJMoa060570

Schroth, 2009, Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen, JAMA, 302, 1429, 10.1001/jama.2009.1420

Ng, 2003, SIFT: predicting amino acid changes that affect protein function, Nucleic Acids Res, 31, 3812, 10.1093/nar/gkg509

Huang, 2010, Prediction of deleterious non-synonymous SNPs based on protein interaction network and hybrid properties, PLoS One, 5, e11900, 10.1371/journal.pone.0011900

Torkamani, 2009, Identification of rare cancer driver mutations by network reconstruction, Genome Res, 19, 1570, 10.1101/gr.092833.109

Sharma, 2006, “Oncogenic shock”: explaining oncogene addiction through differential signal attenuation, Clin Cancer Res, 12, 4392s, 10.1158/1078-0432.CCR-06-0096

Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368

Bang, 2010, Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC), J Clin Oncol, 28, 18s, 10.1200/jco.2010.28.18_suppl.3

Fleming, 2010, Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, 116, 15, 10.1016/j.ygyno.2009.09.025

Joseph, 2010, The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner, Proc Natl Acad Sci U S A, 107, 14903, 10.1073/pnas.1008990107

Iglehart, 2009, Synthetic lethality—a new direction in cancer-drug development, N Engl J Med, 361, 189, 10.1056/NEJMe0903044

Fong, 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers, N Engl J Med, 361, 123, 10.1056/NEJMoa0900212

Gonzalez-Angulo, 2010, Future of personalized medicine in oncology: a systems biology approach, J Clin Oncol, 28, 2777, 10.1200/JCO.2009.27.0777

Hennessy, 2009, A systems approach to analysis of molecular complexity in breast cancer, Clin Cancer Res, 15, 417, 10.1158/1078-0432.CCR-08-2620

Noushmehr, 2010, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell, 17, 510, 10.1016/j.ccr.2010.03.017

Shete, 2009, Genome-wide association study identifies five susceptibility loci for glioma, Nat Genet, 41, 899, 10.1038/ng.407

Wrensch, 2009, Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility, Nat Genet, 41, 905, 10.1038/ng.408

Zheng, 2010, PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas, Cancer Cell, 17, 497, 10.1016/j.ccr.2010.03.020

Zheng, 2008, p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation, Nature, 455, 1129, 10.1038/nature07443

Hudson, 2010, International network of cancer genome projects, Nature, 464, 993, 10.1038/nature08987

Maher, 2009, Transcriptome sequencing to detect gene fusions in cancer, Nature, 458, 97, 10.1038/nature07638

Maher, 2009, Chimeric transcript discovery by paired-end transcriptome sequencing, Proc Natl Acad Sci U S A, 106, 12353, 10.1073/pnas.0904720106

Barker, 1982, Double minutes in human tumor cells, Cancer Genet Cytogenet, 5, 81, 10.1016/0165-4608(82)90043-7

Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9

Gu, 2007, Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature, Hum Mutat, 28, 760, 10.1002/humu.20512

Saddic, 2010, Methylation of the retinoblastoma tumor suppressor by SMYD2, J Biol Chem, 285, 37733, 10.1074/jbc.M110.137612

Sorlie, 2003, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A, 100, 8418, 10.1073/pnas.0932692100

Lossos, 2004, Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes, N Engl J Med, 350, 10.1056/NEJMoa032520

Rosenwald, 2002, The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, N Engl J Med, 346, 1937, 10.1056/NEJMoa012914

Bertucci, 2007, A gene signature in breast cancer, N Engl J Med, 356, 1887, 10.1056/NEJMc070393

Liu, 2007, The prognostic role of a gene signature from tumorigenic breast-cancer cells, N Engl J Med, 356, 217, 10.1056/NEJMoa063994

van de Vijver, 2002, A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med, 347, 1999, 10.1056/NEJMoa021967

Gatza, 2010, A pathway-based classification of human breast cancer, Proc Natl Acad Sci U S A, 107, 6994, 10.1073/pnas.0912708107

Chang, 2009, A genomic strategy to elucidate modules of oncogenic pathway signaling networks, Mol Cell, 34, 104, 10.1016/j.molcel.2009.02.030

Le Beau, 1985, Translocation of the p53 gene in t(15;17) in acute promyelocytic leukaemia, Nature, 316, 826, 10.1038/316826a0

Rowley, 1973, A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining, Nature, 243, 290, 10.1038/243290a0

Winder, 2010, Beyond KRAS: a new approach in metastatic colorectal cancer, Lancet Oncol, 11, 706, 10.1016/S1470-2045(10)70147-9

MacConaill, 2009, Profiling critical cancer gene mutations in clinical tumor samples, PLoS One, 4, e7887, 10.1371/journal.pone.0007887

Dias-Santagata, 2010, Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine, EMBO Mol Med, 2, 146, 10.1002/emmm.201000070

Meyerson, 2010, Advances in understanding cancer genomes through second-generation sequencing, Nat Rev Genet, 11, 685, 10.1038/nrg2841

Ng, 2009, Targeted capture and massively parallel sequencing of 12 human exomes, Nature, 461, 272, 10.1038/nature08250

Wainberg, 2010, Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo, Clin Cancer Res, 16, 1509, 10.1158/1078-0432.CCR-09-1112

Nelson, 2010, Adaptive clinical trial design: has its time come?, J Natl Cancer Inst, 102, 1217, 10.1093/jnci/djq319

Kim, 2010

Mandrekar, 2009, Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges, J Clin Oncol, 27, 4027, 10.1200/JCO.2009.22.3701

Ciaccio, 2010, Systems analysis of EGF receptor signaling dynamics with microwestern arrays, Nat Methods, 7, 148, 10.1038/nmeth.1418